mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment MADRID, May 23, 2018 -- (Healthcare Sales & Marketing Network) -- mAbxience, a company specialize... Biopharmaceuticals, Generics, Licensing mAbxience, Insud Pharma Group, Amneal Pharmaceuticals, bevacizumab, biosimilar
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news